Two coincidentally timed announcements propose good and bad news on ovarian malignant neoplastic disease . Despite not being one of the most rough-cut forms of cancer , ovarian cancer is particularly hard to treat , so it make a disproportionate number of destruction . Now , a new approaching to treatment has passed Phase I clinical trial , but the problem could become worse before it turn over the market , since a separate report find out that chlamydia , whosefrequency is rise , is a risk factor .
Although the ovary are less susceptible to cancer than the breasts or bowel,22,000 Americanwomen are diagnose with the condition each year , with similar rate elsewhere . Moreover , the disease has fewer distinctive former symptoms than many of its counterparts , so by the time it is observe , surgery , chemotherapy , and irradiation may all be command . With less than half of those diagnosed surviving after five years , even with good aesculapian quickness it is a major cause of end . Even pre - emptive activity , such as thattaken by Angelina Jolieto have her ovary removed , doesn’ttotally guaranteeprotection .
In a webinar briefing on research to be present at the American Association for Cancer Research ( AACR ) Annual Meeting in April , Dr Britton Trabertof the National Cancer Instituteannouncedtwo self-governing sketch describe genus Cancer rate are gamy among women with Pgp3 antibodies , which point past chlamydia infection .
Antibodies for a variety of other sexually transmitted infections were not associated with increase risk of ovarian cancer . Given that chlamydia is the most common cause of pelvic inflammatory disease ( PID ) , and PID has been associated with ovarian Cancer the Crab before , the results are unsurprising , but still concern as chlamydia rate increase .
hope for better treatment options climb , however , with the publication inClinical Cancer Researchof a trial run of an immune therapy to handle the disease . Like all Phase I trials , this was done on a small sample of mass , in this case , just 14 . therefore , it ’s too former to say just how good the TPIV200 therapeutic vaccine used in the test really is , particularly since there was no randomised command chemical group .
Nevertheless , the tribulation succeed in its end of generating a lasting immune response , and almost doubled the usual menstruation before disease progression begin . Only one patient get a serious side essence . The findings were sufficiently hopeful and a Phase II trial is already underway . The trial also tested the responses of eight breast Crab patients to the vaccine , with standardized incontrovertible core .
TPIV200 point the Folate Receptor Alpha , entail in ovarian and some boob cancers . It stimulate the immune system ’s helper cells to attack tumors , which should , in theory , produce far fewer side effects than chemotherapy , and has the potential to be extended to many other types of cancer .
